Get started
Author

Zhengke Lian

Observed names: Lian, Zhengke, zhengke lian
ORCID: 0000-0001-8010-4616
Observed ORCID: 0000-0001-8010-4616
OpenAlex ID: A5019882105
Feedback activation of EGFR/wild-type RAS signaling axis limits KRASG12D inhibitor efficacy in KRASG12D-mutated colorectal cancer
2023 · Juanjuan Feng, Zhongwei Hu, et al. · Oncogene · 92
PDF
Targeting metabolic vulnerability in mitochondria conquers MEK inhibitor resistance in KRAS-mutant lung cancer
2022 · Juanjuan Feng, Zhengke Lian, et al. · Acta Pharmaceutica Sinica B · 58
PDF
A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers
2025 · Juanjuan Feng, Xuanzheng Xiao, et al. · Cancer Cell · 38
BCL6 is regulated by the MAPK/ELK1 axis and promotes KRAS-driven lung cancer
2022 · Kun Li, Yanan Liu, et al. · Journal of Clinical Investigation · 36
Loss of PHF8 induces a viral mimicry response by activating endogenous retrotransposons
2023 · Yanan Liu, Longmiao Hu, et al. · Nature Communications · 32
PDF
Pan-KRAS inhibition: unlocking broad-spectrum targeted therapy for KRAS-mutant cancers
2026 · Juanjuan Feng, Xuanzheng Xiao, et al. · Cancer Biology and Medicine
PDF
M3SpaDE: A Multi-Modal Deep Learning Framework for Predicting Spatially Resolved Drug Responses
2026 · Zhang, Zihao, Cui, Xinyu, et al. · Zenodo (CERN European Organization for Nuclear Research)
Works count: 8
Citation count: 256
H-index: 5
I10-index: 5
Year
Topic
Type